Læknablaðið - 15.05.2005, Síða 54

SPIRIVA"
er grunnurinn í
meðhöndlun á LLT12)
Minnkar mæði við áreynslu3’
Eykur þol eftir áreynslu31
Fækkar versnunum og innlögnum
vegna þeirra41
Eykur lífsgæði sjúklings5’
Meira loft í lungun
Heimildir: I) Medicinsk Kompendium 2004; bls 1331. 2) Tashkin et al. Review.The Role of Long-Acting Bronchodilators in the Management of Stable COPD. CHEST 2004;125:249-259. 3) O'Donnell et al. Effects of tiotropium on lung hyperinflatioF
dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840. 4) Casaburi et al.A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224. 5) Vincken et al. Improved healt1'
outcomes in patients with COPD during I years treatment with tiotropium. Eur Respir J 2002;19:209-216.

Umboðsaðili: PharmaNor hf.
Hörgatúni 2,210 Garðabær
Sími: 535 7000, www.pfizer.is
Sérlyfjatexti á bls. 482
'IfjN Boehringc
illlliv Ingelhein1